Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Research on the links between tenofovir and other antiretrovirals, SARS-CoV-2 infection and COVID severity has produced mixed results.
Using two instead of three or four drugs could potentially lead to cost savings in the billions.
Only a small proportion of people who start treatment very early might be eligible for dolutegravir monotherapy.
The all-oral regimen maintained viral suppression in people with resistance to multiple antiretrovirals.
People treated with Biktarvy were more likely to achieve an undetectable HBV viral load than those on a dolutegravir-based regimen.
The approval makes this the first single-pill regimen containing dolutegravir available in a water-dispersible formulation.
Compared to other common HIV treatments, dolutegravir-based regimens maintained viral suppression even without perfect adherence.
People who switched to such a regimen gained up to 10 pounds in nine months.
The small single-site study will need to be replicated in a larger group of adolescents.
Many participants on two-drug regimens had more treatment under their belt and more chronic conditions.
Study results confirm that dolutegravir is a safe and effective treatment for pregnant women with HIV.
People whose viral load rebounds on Tivicay may not need to switch medications.
The findings highlight an ongoing need for better integration of HIV care with sexual and reproductive health care.
These two integrase inhibitors are associated with high blood sugar and diabetes.
ViiV’s two-drug Dovato also boasted a high genetic barrier to the development of viral resistance.
Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.